Preoperative clinical variables in 223 patients with MMM who underwent therapeutic splenectomy
| Variable . | Value . |
|---|---|
| Age, median (range), y | |
| At diagnosis of MMM | 61.4 (18.6-82) |
| At time of splenectomy | 64.8 (18.6-82) |
| Sex: male/female, no. (%) | 121 (54.3)/102 (45.7) |
| Type of MMM, no. (%) of patients | |
| AMM | 159 (71.3) |
| PPMM | 48 (21.5) |
| PTMM | 16 (7.2) |
| Palpable spleen size, median (range), cm below LCM | 20 (0-32) |
| Spleen mass, median (range), g | 2700 (380-7735) |
| Palpable liver size, median (range), cm below RCM | 3 (0-15) |
| Ascites, no. (%) of patients | |
| Yes | 26 (11.7) |
| No | 197 (88.3) |
| Red blood cell transfusion requirement, no. (%) of patients | |
| Yes | 75 (33.6) |
| No | 148 (66.4) |
| No. of transfusion units/mo, median (range) | 2 (1-8) |
| Hemoglobin, median (range), g/L | 104 (49-178) |
| White blood cell count, median (range), × 109/L | 12.5 (0.9-163) |
| Platelet count, median (range), × 109/L | 140 (2-770) |
| Circulating blasts, median (range), % | 1 (0-14) |
| Alkaline phosphatase, median (range), U/L | 204 (85-787) |
| Aspartate aminotransferase, median (range), U/L | 26 (10-139) |
| Time from BM biopsy to splenectomy, median (range), mo (n = 206) | 1.2 (0-139) |
| Presplenectomy cellularity, no. (%) of patients (n = 199) | |
| Hypocellular | 50 (25.1) |
| Normocellular | 13 (6.5) |
| Hypercellular | 136 (68.4) |
| Presplenectomy % of myeloblasts in marrow, no. (%) of patients (n = 177) | |
| < 5% | 164 (92.7) |
| ≥ 5% | 13 (7.3) |
| Presplenectomy fibrosis grade on reticulin staining, no. (%) of patients (n = 162) | |
| 1 | 8 (4.9) |
| 2 | 40 (24.7) |
| 3 | 70 (43.2) |
| 4 | 44 (27.2) |
| Time from BM cytogenetic study to splenectomy, median (range), mo (n = 62) | 1 (0-72) |
| Normal cytogenetic results, no. (%) of patients | 27 (43.5) |
| Abnormal cytogenetic results, no. (%) of patients | 35 (56.5) |
| Constitutional symptoms, no. (%) of patients | |
| Fatigue | 218 (97.8) |
| Night sweats | 62 (27.8) |
| Fever | 22 (9.9) |
| Bone pain | 10 (4.5) |
| Weight loss, median (range), kg | 4.5 (0-13.6) |
| Indication for surgery, no. (%) of patients | |
| Anemia | 101 (45.3) |
| Symptomatic splenomegaly | 87 (39.0) |
| Portal hypertension | 24 (10.8) |
| Severe thrombocytopenia | 11 (4.9) |
| Time from diagnosis to splenectomy, median (range), mo (n = 223) | 24.7 (0-385) |
| Follow-up period after diagnosis, median (range), mo (n = 223) | 50.3 (0.3-479) |
| Follow-up period after splenectomy, median (range), mo (n = 201) | 14.4 (0.2-157) |
| Variable . | Value . |
|---|---|
| Age, median (range), y | |
| At diagnosis of MMM | 61.4 (18.6-82) |
| At time of splenectomy | 64.8 (18.6-82) |
| Sex: male/female, no. (%) | 121 (54.3)/102 (45.7) |
| Type of MMM, no. (%) of patients | |
| AMM | 159 (71.3) |
| PPMM | 48 (21.5) |
| PTMM | 16 (7.2) |
| Palpable spleen size, median (range), cm below LCM | 20 (0-32) |
| Spleen mass, median (range), g | 2700 (380-7735) |
| Palpable liver size, median (range), cm below RCM | 3 (0-15) |
| Ascites, no. (%) of patients | |
| Yes | 26 (11.7) |
| No | 197 (88.3) |
| Red blood cell transfusion requirement, no. (%) of patients | |
| Yes | 75 (33.6) |
| No | 148 (66.4) |
| No. of transfusion units/mo, median (range) | 2 (1-8) |
| Hemoglobin, median (range), g/L | 104 (49-178) |
| White blood cell count, median (range), × 109/L | 12.5 (0.9-163) |
| Platelet count, median (range), × 109/L | 140 (2-770) |
| Circulating blasts, median (range), % | 1 (0-14) |
| Alkaline phosphatase, median (range), U/L | 204 (85-787) |
| Aspartate aminotransferase, median (range), U/L | 26 (10-139) |
| Time from BM biopsy to splenectomy, median (range), mo (n = 206) | 1.2 (0-139) |
| Presplenectomy cellularity, no. (%) of patients (n = 199) | |
| Hypocellular | 50 (25.1) |
| Normocellular | 13 (6.5) |
| Hypercellular | 136 (68.4) |
| Presplenectomy % of myeloblasts in marrow, no. (%) of patients (n = 177) | |
| < 5% | 164 (92.7) |
| ≥ 5% | 13 (7.3) |
| Presplenectomy fibrosis grade on reticulin staining, no. (%) of patients (n = 162) | |
| 1 | 8 (4.9) |
| 2 | 40 (24.7) |
| 3 | 70 (43.2) |
| 4 | 44 (27.2) |
| Time from BM cytogenetic study to splenectomy, median (range), mo (n = 62) | 1 (0-72) |
| Normal cytogenetic results, no. (%) of patients | 27 (43.5) |
| Abnormal cytogenetic results, no. (%) of patients | 35 (56.5) |
| Constitutional symptoms, no. (%) of patients | |
| Fatigue | 218 (97.8) |
| Night sweats | 62 (27.8) |
| Fever | 22 (9.9) |
| Bone pain | 10 (4.5) |
| Weight loss, median (range), kg | 4.5 (0-13.6) |
| Indication for surgery, no. (%) of patients | |
| Anemia | 101 (45.3) |
| Symptomatic splenomegaly | 87 (39.0) |
| Portal hypertension | 24 (10.8) |
| Severe thrombocytopenia | 11 (4.9) |
| Time from diagnosis to splenectomy, median (range), mo (n = 223) | 24.7 (0-385) |
| Follow-up period after diagnosis, median (range), mo (n = 223) | 50.3 (0.3-479) |
| Follow-up period after splenectomy, median (range), mo (n = 201) | 14.4 (0.2-157) |
AMM indicates agnogenic myeloid metaplasia; PPMM, postpolycythemic myeloid metaplasia; PTMM, postthrombocythemic myeloid metaplasia; LCM, left costal margin; RCM, right costal margin; and BM, bone marrow.